,address1,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Dr. Antti  Vuolanto D.Sc. (Tech)', 'age': 47, 'title': 'CEO & COO', 'yearBorn': 1975, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
1,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Ms. Tone  Kvale', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
2,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Dr. Henri J. Huttunen', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
3,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Ms. Sigrid  Booms', 'title': 'Head of Regulatory Affairs & Compliance', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
4,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Ms. Jutta  Poutanen', 'title': 'Head of Quality', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
5,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Mr. Jani  Koskinen', 'title': 'Head of CMC', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
6,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Ms. Outi  Lahdenper√§ M.D., Ph.D.', 'title': 'Chief Medical Ofcer', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
7,Bertel Jungin Aukio 1,Espoo,02600,Finland,358 9222 1195,https://herantis.com,Biotechnology,Healthcare,"Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.",10,"{'maxAge': 1, 'name': 'Dr. Charlotte  Videbaek M.D.', 'age': 60, 'title': 'Clinical Consultant', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,1.515,1.515,1.495,1.52,1.515,1.515,1.495,1.52,0.0,0.427552,1.4851485,2152,2152,5362,5037,5037,1.495,1.51,25412400,1.4,3.04,90.75857,1.5752,2.000975,0.0,0.0,EUR,25000592,0.0,11157275,16941600,0.32702,0.32694998,-0.11,1672444800,1703980800,1688083200,-5454225,1.01,89.288,HEL,EQUITY,HRTIS.HE,HRTIS.HE,Herantis Pharma Oyj,Herantis Pharma Oyj,1402470000,Europe/Helsinki,EEST,10800000,1.5,2.4,2.4,2.4,2.4,none,1,4909000,0.29,4541000,1.877,1.887,280000,0.017,-0.47437,-170.44453,-2864146,-5143913,1.0,0.0,-21.54201,EUR,
